| Symbol | APRE |
|---|---|
| Name | APREA THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 535 BOYLSTON STREET, BOSTON, Massachusetts, 02116, United States |
| Telephone | +1 617 463-9385 |
| Fax | — |
| — | |
| Website | https://www.aprea.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001781983 |
| Description | Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). Additional info from NASDAQ: |
(99% Positive) APREA THERAPEUTICS, INC. (APRE) Announces Enrollment Update for options Due to Patient Enrollment Issues, Regulatory Process, Safety Review
Read moreAprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs
Read moreNew Form SCHEDULE 13G/A - Aprea Therapeutics, Inc. <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0000935836-26-000399 <b>Size:</b> 6 KB
Read more(30% Negative) APREA THERAPEUTICS, INC. (APRE) Reports Q3 2026 Financial Results
Read moreDirector Grissinger Michael 🟢 acquired 15.7K shares (1 derivative) of Aprea Therapeutics, Inc. (APRE) at $0.73 Transaction Date: Jun 16, 2026 | Filing ID: 075286
Read moreDirector Gruia Gabriela 🟢 acquired 15.7K shares (1 derivative) of Aprea Therapeutics, Inc. (APRE) at $0.73 Transaction Date: Jun 16, 2026 | Filing ID: 075284
Read moreDirector Peters Richard 🟢 acquired 15.7K shares (1 derivative) of Aprea Therapeutics, Inc. (APRE) at $0.73 Transaction Date: Jun 16, 2026 | Filing ID: 075283
Read moreDirector HENNEMAN JOHN B III 🟢 acquired 15.7K shares (1 derivative) of Aprea Therapeutics, Inc. (APRE) at $0.73 Transaction Date: Jun 16, 2026 | Filing ID: 075282
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07617363 | ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Hi… | Phase1 | Acute Myeloid Leukemia | Not_Yet_Recruiting | 2026-08-31 | 2031-12-31 | ClinicalTrials.gov |
| NCT07578467 | Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectabl… | Phase1 | HPV Positive Oropharyngeal Squamous Cell Carcinoma | Not_Yet_Recruiting | 2026-08-31 | 2030-08-31 | ClinicalTrials.gov |
| NCT06260514 | Study of APR-1051 in Patients With Advanced Solid Tumors | Phase1 | Advanced Solid Tumor | Recruiting | 2024-06-13 | 2028-06-01 | ClinicalTrials.gov |
| NCT04905914 | Study Of ATRN-119 In Patients With Advanced Solid Tumors | Phase1 | Advanced Solid Tumor | Completed | 2023-01-09 | 2026-03-09 | ClinicalTrials.gov |
| NCT04638309 | APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplast… | Phase1 | MDS | Terminated | 2021-09-20 | 2022-04-25 | ClinicalTrials.gov |
| NCT04419389 | APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjec… | Phase1 | Non Hodgkin Lymphoma | Terminated | 2021-03-02 | 2021-08-24 | ClinicalTrials.gov |
| NCT04383938 | Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With S… | Phase1 | Bladder Cancer | Completed | 2020-06-25 | 2022-04-30 | ClinicalTrials.gov |
| NCT04214860 | APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid M… | Phase1 | Myeloid Malignancy | Completed | 2019-12-13 | 2022-01-14 | ClinicalTrials.gov |
| NCT03931291 | APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leu… | Phase2 | Acute Myeloid Leukemia or Myelodysplastic Syndromes | Completed | 2019-09-16 | 2022-01-14 | ClinicalTrials.gov |
| NCT03745716 | APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndrome… | Phase3 | MDS | Completed | 2019-01-11 | 2022-01-14 | ClinicalTrials.gov |
| NCT03588078 | Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine | Phase1 | Myelodysplastic Syndrome With Gene Mutation | Unknown | 2018-09-15 | 2021-05-15 | ClinicalTrials.gov |
| NCT03391050 | A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BR… | Phase1 | Melanoma | Terminated | 2018-01-18 | 2018-08-08 | ClinicalTrials.gov |
| NCT03268382 | p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study … | Phase2 | High-grade Serous Ovarian Cancer | Completed | 2017-07-31 | 2019-07-10 | ClinicalTrials.gov |
| NCT03072043 | Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant M… | Phase1 | Myelodysplastic Syndrome | Completed | 2017-05-18 | 2021-12-08 | ClinicalTrials.gov |
| NCT02098343 | p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phas… | Phase1 | Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53 | Completed | 2014-03-01 | 2019-04-01 | ClinicalTrials.gov |
| NCT00900614 | Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prost… | Phase1 | Hematologic Neoplasms | Completed | 2009-05-01 | 2010-10-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| APR-1051 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06260514 |
| ATRN-119 | Other | Phase PHASE1 | Advanced Solid Tumor | COMPLETED | NCT04905914 |
| Stereotactic Body Radiation Therapy (SBRT) | Drug | Phase PHASE1 | HPV Positive Oropharyngeal Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07578467 |
| ATRN-119 | Other | Phase PHASE1 | HPV Positive Oropharyngeal Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07578467 |
| Stereotactic Body Radiation Therapy (SBRT) | Drug | Phase PHASE1 | HPV Positive Oropharyngeal Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07578467 |
| ATRN-119 | Other | Phase PHASE1 | HPV Positive Oropharyngeal Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07578467 |
| Decitabine | Other | Phase PHASE1 | Acute Myeloid Leukemia | NOT_YET_RECRUITING | NCT07617363 |
| ATRN-119 | Other | Phase PHASE1 | Acute Myeloid Leukemia | NOT_YET_RECRUITING | NCT07617363 |
| Stereotactic Body Radiation Therapy (SBRT) | Drug | Phase PHASE1 | HPV Positive Oropharyngeal Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07578467 |
| ATRN-119 | Other | Phase PHASE1 | HPV Positive Oropharyngeal Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07578467 |
| Stereotactic Body Radiation Therapy (SBRT) | Drug | Phase PHASE1 | HPV Positive Oropharyngeal Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07578467 |
| ATRN-119 | Other | Phase PHASE1 | HPV Positive Oropharyngeal Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07578467 |
| Stereotactic Body Radiation Therapy (SBRT) | Drug | Phase PHASE1 | HPV Positive Oropharyngeal Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07578467 |
| ATRN-119 | Other | Phase PHASE1 | HPV Positive Oropharyngeal Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07578467 |
| Stereotactic Body Radiation Therapy (SBRT) | Drug | Phase PHASE1 | HPV Positive Oropharyngeal Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07578467 |
| ATRN-119 | Other | Phase PHASE1 | HPV Positive Oropharyngeal Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07578467 |
| Stereotactic Body Radiation Therapy (SBRT) | Drug | Phase PHASE1 | HPV Positive Oropharyngeal Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07578467 |
| ATRN-119 | Other | Phase PHASE1 | HPV Positive Oropharyngeal Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07578467 |
| Stereotactic Body Radiation Therapy (SBRT) | Drug | Phase PHASE1 | HPV Positive Oropharyngeal Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07578467 |
| ATRN-119 | Other | Phase PHASE1 | HPV Positive Oropharyngeal Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07578467 |
| Dabrafenib | Other | Phase PHASE1 | Melanoma | TERMINATED | NCT03391050 |
| APR-246 | Other | Phase PHASE1 | Melanoma | TERMINATED | NCT03391050 |
| Azacitidine | Other | Phase PHASE1 | Myelodysplastic Syndrome With Gene Mutation | UNKNOWN | NCT03588078 |
| APR-246 | Other | Phase PHASE1 | Myelodysplastic Syndrome With Gene Mutation | UNKNOWN | NCT03588078 |
| Azacitidine | Other | Phase PHASE1 | Myelodysplastic Syndrome | COMPLETED | NCT03072043 |
| APR-246 | Other | Phase PHASE1 | Myelodysplastic Syndrome | COMPLETED | NCT03072043 |
| APR-548 + Azacitidine | Other | Phase PHASE1 | MDS | TERMINATED | NCT04638309 |
| APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in RT | Other | Phase PHASE1 | Non Hodgkin Lymphoma | TERMINATED | NCT04419389 |
| APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT | Other | Phase PHASE1 | Non Hodgkin Lymphoma | TERMINATED | NCT04419389 |
| APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL | Other | Phase PHASE1 | Non Hodgkin Lymphoma | TERMINATED | NCT04419389 |
| APR-246 (eprenetapopt) + Acalabrutinib in CLL | Other | Phase PHASE1 | Non Hodgkin Lymphoma | TERMINATED | NCT04419389 |
| Azacitidine | Other | Phase PHASE1 | Myeloid Malignancy | COMPLETED | NCT04214860 |
| Venetoclax | Other | Phase PHASE1 | Myeloid Malignancy | COMPLETED | NCT04214860 |
| APR-246 | Other | Phase PHASE1 | Myeloid Malignancy | COMPLETED | NCT04214860 |
| APR-246 | Other | Phase PHASE2 | Acute Myeloid Leukemia or Myelodysplastic Syndromes | COMPLETED | NCT03931291 |
| Pegylated Liposomal Doxorubicin Hydrochloride (PLD) | Other | Phase PHASE2 | High-grade Serous Ovarian Cancer | COMPLETED | NCT03268382 |
| APR-246 | Other | Phase PHASE2 | High-grade Serous Ovarian Cancer | COMPLETED | NCT03268382 |
| Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD) | Other | Phase PHASE1 | Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53 | COMPLETED | NCT02098343 |
| APR-246 | Other | Phase PHASE1 | Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53 | COMPLETED | NCT02098343 |
| Azacitidine | Other | Phase PHASE3 | MDS | COMPLETED | NCT03745716 |
| APR-246 + azacitidine | Other | Phase PHASE3 | MDS | COMPLETED | NCT03745716 |
| APR-246 (eprenetapopt) + Pembrolizumab | Other | Phase PHASE1 | Bladder Cancer | COMPLETED | NCT04383938 |
| ATRN-119 | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04905914 |
| APR-1051 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06260514 |
| APR-1051 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06260514 |
| APR-1051 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06260514 |
| APR-1051 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06260514 |
| APR-1051 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06260514 |
| APR-1051 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06260514 |
| APR-1051 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06260514 |
| APR-1051 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06260514 |
| APR-1051 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06260514 |
| APR-1051 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06260514 |
| APR-1051 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06260514 |
| APR-1051 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06260514 |
| APR-1051 | DRUG | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06260514 |
| ATRN-119 | DRUG | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04905914 |
| APR-548 + Azacitidine | DRUG | Phase PHASE1 | MDS | TERMINATED | NCT04638309 |
| APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in RT | DRUG | Phase PHASE1 | Non Hodgkin Lymphoma | TERMINATED | NCT04419389 |
| APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT | DRUG | Phase PHASE1 | Non Hodgkin Lymphoma | TERMINATED | NCT04419389 |
| APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL | DRUG | Phase PHASE1 | Non Hodgkin Lymphoma | TERMINATED | NCT04419389 |
| APR-246 (eprenetapopt) + Acalabrutinib in CLL | DRUG | Phase PHASE1 | Non Hodgkin Lymphoma | TERMINATED | NCT04419389 |
| APR-246 (eprenetapopt) + Pembrolizumab | DRUG | Phase PHASE1 | Bladder Cancer | COMPLETED | NCT04383938 |
| Venetoclax | DRUG | Phase PHASE1 | Myeloid Malignancy | COMPLETED | NCT04214860 |
| APR-246 + azacitidine | DRUG | Phase PHASE3 | MDS | COMPLETED | NCT03745716 |
| Dabrafenib | DRUG | Phase PHASE1 | Melanoma | TERMINATED | NCT03391050 |
| Pegylated Liposomal Doxorubicin Hydrochloride (PLD) | DRUG | Phase PHASE2 | High-grade Serous Ovarian Cancer | COMPLETED | NCT03268382 |
| Azacitidine | DRUG | Phase PHASE1 | Myeloid Malignancy | COMPLETED | NCT04214860 |
| Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD) | DRUG | Phase PHASE1 | Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53 | COMPLETED | NCT02098343 |
| APR-246 | DRUG | Phase PHASE1 | Myeloid Malignancy | COMPLETED | NCT04214860 |